Corpus Intelligence IC Memo — ST. ROSE DOMINICAN - DELIMA 2026-04-26 05:30 UTC
IC Memo — ST. ROSE DOMINICAN - DELIMA
Investment Committee Memorandum | NV | 10 beds | Grade D | EBITDA uplift $1.6M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

ST. ROSE DOMINICAN - DELIMA

CCN 290012 | CLARK, NV | 10 beds | April 26, 2026
EBITDA BridgeData Room
D
Investability

1. Target Overview & Investment Thesis

ST. ROSE DOMINICAN - DELIMA is a 10-bed safety-net/medicaid heavy in CLARK, NV with $21.8M in net patient revenue and a -45.3% operating margin. The hospital serves a payer mix of 8.3% Medicare, 35.3% Medicaid, and 56.3% commercial.

Thesis: Turnaround. Our ML models identify $1.6M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -45.3% to -37.9% (+736bps).

Net Revenue HCRIS$21.8M
Current EBITDA COMPUTED$-9.9M
Operating Margin COMPUTED-45.3%
Occupancy HCRIS41.7%
Revenue / Bed COMPUTED$2.2M
Net-to-Gross HCRIS10.5%
Distress Probability ML53.1%

2. Market Context & Competitive Position

58
NV Hospitals
0.4%
State Median Margin
616
Comparable Hospitals

NV has 58 Medicare-certified hospitals with a median operating margin of 0.4%. The target's margin of -45.3% places it below the state median. Among 616 size-comparable peers (5-20 beds), the median margin is -8.7%. The target's below-peer margin suggests operational improvement opportunity.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (5-20), prioritizing same-state peers. 616 hospitals in the comp set.

HospitalStateBedsRevenueMargin
ST. ROSE DOMINICAN - DELIMA (Target)NV10$21.8M-45.3%
FRED HUTCHINSON CANCER CENTERWA20$1.17B-50.0%
WENATCHEE VALLEY HOSPITALWA11$277.5M-4.9%
PORTERVILLE DEVELOPMENTAL CENTCA17$193.6M-6.0%
NATIONAL JEWISH HEALTHCO13$150.4M-50.0%
NORTON SOUND REGIONAL HOSPITALAK18$148.7M-28.6%
TEXAS SPINE AND JOINT HOSPITALTX20$147.3M30.3%
GREAT FALLS CLINIC MEDICAL CENMT20$132.1M21.0%
MARSHFIELD MEDICAL CENTER-MINOWI19$129.6M-12.4%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $1.6M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$457K+210bp18mo
Cost to Collect4.5%2.5%$435K+200bp12mo
Denial Rate Reduction12.0%6.5%$431K+198bp12mo
A/R Days Reduction5200.0%3800.0%$265K+122bp9mo
Clean Claim Rate88.0%96.0%$14K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$457K
Cost to Collect
$435K
Denial Rate Reduction
$431K
A/R Days Reduction
$265K
Clean Claim Rate
$14K
Total EBITDA Uplift$1.6M
Current EBITDA$-9.9M
+ RCM Uplift+$1.6M
Pro Forma EBITDA$-8.3M
Current Margin-45.3%
Pro Forma Margin-37.9%
WC Released (1x)$835K

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$-15.2M$-49.0M0.00x-100.0%
Base (11x exit)10.0x11.0x$-15.2M$-58.9M0.00x-100.0%
Bull Case9.0x11.0x$-13.7M$-58.5M0.00x-100.0%
Bull (12x exit)9.0x12.0x$-13.7M$-67.8M0.00x-100.0%
Bear Case11.0x10.0x$-16.7M$-52.1M0.00x-100.0%
Bear (11x exit)11.0x11.0x$-16.7M$-62.7M0.00x-100.0%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
HighNegative operating marginRCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion
MediumElevated Medicaid exposure (35.3%)Medicaid reimburses below cost in most states. Mitigant: denial reduction lever has highest impact on Medicaid claims
HighElevated distress probabilityModel estimates 53.1% probability of financial distress. Mitigant: distressed entry pricing (7-9x) compensates for risk
LowLow net-to-gross ratioLarge contractual allowances suggest pricing discipline issues. Mitigant: payer renegotiation is an additional upside lever

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 616 hospitals with 5-20 beds
  • Same-state prioritization (n=6)
  • Comp margins: P25=-24.1% / P50=-8.7% / P75=2.2%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.